AMENDMENTS TO THE CLAIMS

1-20. **(Cancelled)**.

21. **(New)** A compound of the following formula (1):



in which

m and n each independently represents 1 or 2,

R^1 represents

hydrogen;

heterocycle which is unsubstituted, or mono- or polysubstituted by substituents selected from halogen and C_1-C_{10}-alkyl;

$-(CH_2)_{1-3}-R^6$, wherein R^6 is selected from the group consisting of hydrogen, C_1-C_{10}-alkyl, C_1-C_8-alkoxy, heterocycle, hydroxy, C_1-C_8-alkoxylcarbonyl, carboxy, amino, C_1-C_{10}-alkylamino, di(C_1-C_{10}-alkyl)amino, and C_1-C_8-alkylcarbonylamino; wherein heterocycle is substituted by one or more substituents selected from the group consisting of halogen, oxo, hydroxy, C_1-C_{10}-alkyl, C_1-C_8-alkylcarbonyl and C_6-C_{10}-aryloxy;

glycine, alanine, histidine, phenylalanine or proline; wherein one or more hydrogen atoms on nitrogen atom are unsubstituted or substituted by a substituent selected from the group consisting of C_1-C_{10}-alkyl, C_1-C_8-alkylcarbonyl, C_1-C_8-alkoxycarbonyl and C_1-C_8-alkylsulfonyl; or

$-SO_2-C_1-C_3$-alkyl,

R^2 represents

hydrogen;

C_1-C_8-alkyl;

-CO-$(CH_2)_{1-3}$-hydroxy; or

-CH_2-CO-hydroxy,

R^3 represents

C_1-C_8-alkyl which is unsubstituted, or mono- or polysubstituted by substituents selected from C_1-C_8-alkyl and carbamoyl;

-$(CH_2)_{1-3}$-C_3-C_8-cycloalkyl; or

-$(CH_2)_{0-3}$-C_6-C_{10}-aryl which is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of halogen, hydroxy, C_1-C_8-alkoxy and C_1-C_8-alkyl,

R^4 represents

C_1-C_8-alkyl;

-$(CH_2)_{1-3}$-C_3-C_8-cycloalkyl;

C_3-C_8-cycloalkyl which is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of halogen, C_1-C_8-alkyl and C_6-C_{10}-aryl;

spiro[2,5]octan; or

heterocycle,

R^5 represents

carbonyl substituted by a substituent selected from the group consisting of C_1-C_8-alkyl, C_1-C_6 alkoxy, C_3-C_7-cycloalkyl, heterocycle and C_6-C_{10}-aryl unsubstituted or substituted by hydroxy; wherein alkyl is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of amino, C_1-C_8-alkylamino, di(C_1-C_8-alkyl)amino, hydroxy, C_1-C_8-alkoxy, C_6-C_{10}-ar C_1-C_8-alkyloxy, C_1-C_8-alkyl C_6-C_{10}-aryloxy, C_6-C_{10}-aryloxy, C_6-C_{10}-arylthio, formyl, C_2-C_8-alkanoyloxy, C_3-C_8-cycloalkylcarbonyloxy, C_6-C_{10}-arylcarbonyloxy unsubsituted or substituted by halogen, C_6-C_{10}-ar C_1-C_8-alkylcarbonyloxy; cycloalkyl is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of hydroxycarbonyl, C_1-C_8-alkoxycarbonyl,

hydroxyl-C_1-C_8-alkyl; and heterocycle is unsubstituted, or mono- or polysubstituted by the substituents selected from the group consisting of hydroxy, hydroxyC_1-C_8-alkyl, amino and 2-nitrobenzenesulfonyl;

-$(CH_2)_{1-3}$-C(=O)-C_1-C_6-alkoxy;

carbamoyl which is mono- or polysubstituted by substituents selected from the group consisting of hydrogen, C_1-C_8-alkyl, C_1-C_6-alkoxy, C_3-C_7-cycloalkyl, C_6-C_{10}-aryl and C_1-C_8-alkylcarbonyl substituted by hydroxy; wherein alkyl is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of halogen, hydroxy, amino and C_1-C_8-alkoxy;

-$(CH_2)_{1-3}$-C(=O)N(C_1-C_8-alkyl)(C_1-C_8-alkyl);

-C(=S)N(H)(C_1-C_8-alkyl) or -C(=S)N(H)(C_1-C_8-alkyl)(C_1-C_8-alkyl); or

-SO_2-NH_2 or –$(CH_2)_{0-3}$-SO_2-C_1-C_8alkyl,

wherein heterocycle includes 1 to 2 heteroatom(s) from the group consisting of nitrogen atom, oxygen atom and sulfur atom, and represents 4- to 8-membered ring which can be fused with benzo or C_3-C_8-cycloalkyl, and which is saturated or has 1 or 2 double bond, or

a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

22. (**New**) The compound according to claim 21, wherein

R^1 represents

hydrogen; or

-$(CH_2)_{1-3}$-R^6, wherein R^6 selected from the group consisting of hydrogen, C_1-C_{10}-alkyl, C_1-C_8-alkoxy, heterocycle, hydroxy, C_1-C_8-alkoxylcarbonyl, carboxy, amino, C_1-C_{10}-alkylamino, di(C_1-C_{10}-alkyl)amino, and C_1-C_8-alkylcarbonylamino; wherein heterocycle is substituted by one or more substituents selected from the group consisting of halogen, oxo, hydroxy, C_1-C_{10}-alkyl, C_1-C_8-alkylcarbonyl and C_6-C_{10}-aryloxy; or

a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

23. (**New**) The compound according to claim 21, wherein
R^2 represents hydrogen or C_1-C_6-alkyl, or
a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

24. (**New**) The compound according to claim 21, wherein
R^3 represents $-CH_2$-phenyl which is unsubstituted or mono- to tri-substituted by substituents selected from the group consisting of chloro, bromo, hydroxy, methoxy and methyl, or
a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

25. (**New**) The compound according to claim 21, wherein
R^4 represents C_3-C_8-cycloalkyl which is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of halogen, C_1-C_8-alkyl and C_6-C_{10}-aryl, or
a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

26. (**New**) The compound according to claim 21, wherein
R^5 represents carbonyl substituted by the substituent selected from the group consisting of C_1-C_8-alkyl, C_1-C_6-alkoxy, C_3-C_7-cycloalkyl, heterocycle and C_6-C_{10}-aryl unsubstituted or substituted by hydroxy; wherein alkyl is unsubstituted, or mono- or polysubstituted by the substituents selected from the group consisting of amino, C_1-C_6-alkylamino, di(C_1-C_6-alkyl)amino, hydroxy, C_1-C_8-alkoxy, C_6-C_{10}-ar C_1-C_8-alkyloxy, C_1-C_8-alkyl C_6-C_{10}-aryloxy, C_6-C_{10}-aryloxy, C_6-C_{10}-arylthio, formyl, C_2-C_8-alkanoyloxy, C_3-C_8-cycloalkylcarbonyloxy, C_6-C_{10}-arylcarbonyloxy unsubsituted or substituted by halogen, C_6-C_{10}-ar C_1-C_8-alkylcarbonyloxy; cycloalkyl is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of hydroxycarbonyl, C_1-C_8-alkoxycarbonyl, hydroxyl- C_1-C_8-alkyl; and heterocycle is unsubstituted, or mono- or polysubstituted by the substituents selected from the group consisting of hydroxy, hydroxyC_1-C_8-alkyl, amino and 2-nitrobenzenesulfonyl, or

a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

27. (New) An agonistic composition of melanocortin receptor comprising the compound of formula (1), or a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof as defined in claim 21 together with a pharmaceutically acceptable carrier.